Latest & greatest articles for atrial fibrillation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on atrial fibrillation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on atrial fibrillation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for atrial fibrillation

1021. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. The European Atrial Fibrillation Trial Study Group. (PubMed)

Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. The European Atrial Fibrillation Trial Study Group. A number of studies have demonstrated the efficacy of oral anticoagulant therapy in reducing the risk of stroke and systemic embolism in patients with nonrheumatic atrial fibrillation. However, both the targeted and the actual levels of anticoagulation differed widely among the studies, and a number of studies failed to report (...) standardized prothrombin-time ratios as international normalized ratios (INRs). We therefore performed an analysis to determine the intensity of oral anticoagulant therapy in nonrheumatic atrial fibrillation that provides the best balance between the prevention of thromboembolism and the occurrence of bleeding complications.We calculated INR-specific incidence rates for both ischemic and major hemorrhagic events occurring in 214 patients who received anticoagulant therapy in the European Atrial

Full Text available with Trip Pro

1995 NEJM

1022. Treatment of resistant atrial fibrillation: a meta-analysis comparing amiodarone and flecainide

Treatment of resistant atrial fibrillation: a meta-analysis comparing amiodarone and flecainide Treatment of resistant atrial fibrillation: a meta-analysis comparing amiodarone and flecainide Treatment of resistant atrial fibrillation: a meta-analysis comparing amiodarone and flecainide Zarembski D G, Nolan P E, Slack M K, Caruso A C Authors' objectives To compare the efficacies of two antiarrhythmic drug therapies, amiodarone hydrochloride and flecainide acetate, in maintaining normal sinus (...) rhythm in patients with resistant chronic atrial fibrillation. Searching Current Contents: Clinical Practice was reviewed and MEDLINE was searched from January 1983 to August 1993 for English language studies. Bibliographies of identified articles were searched to locate additional articles. Study selection Study designs of evaluations included in the review Prospective clinical trials were included. Specific interventions included in the review Amiodarone hydrochloride and flecainide acetate

1995 DARE.

1023. Limitations of transesophageal echocardiography in the risk assessment of patients before nonanticoagulated cardioversion from atrial fibrillation and flutter: an analysis of pooled trials

Limitations of transesophageal echocardiography in the risk assessment of patients before nonanticoagulated cardioversion from atrial fibrillation and flutter: an analysis of pooled trials Limitations of transesophageal echocardiography in the risk assessment of patients before nonanticoagulated cardioversion from atrial fibrillation and flutter: an analysis of pooled trials Limitations of transesophageal echocardiography in the risk assessment of patients before nonanticoagulated cardioversion (...) from atrial fibrillation and flutter: an analysis of pooled trials Moreyra E, Finkelhor R S, Cebul R D Authors' objectives To compare the embolic risk from the pooled results of transesophageal echocardiography (TEE) trials with that of historical controls with blind cardioversion in anticoagulated or nonanticoagulated participants. Searching MEDLINE was searched from 1966 to 1993 for English language studies using the following search headings: 'transesophageal echocardiography', 'atrial

1995 DARE.

1024. Anticoagulation for stroke prevention in chronic non-valvular atrial fibrillation

Anticoagulation for stroke prevention in chronic non-valvular atrial fibrillation Anticoagulation for stroke prevention in chronic non-valvular atrial fibrillation Anticoagulation for stroke prevention in chronic non-valvular atrial fibrillation Green C J, Hadorn D, Kazanjian A Authors' objectives To assess the evidence concerning the outcomes associated with efforts to prevent the occurrence of stroke in patients with chronic non-valvular atrial fibrillation using warfarin sodium. Searching (...) MEDLINE was searched from 1987 to 1994 using the keywords: 'atrial fibrillation', 'anticoagulants', 'aspirin'). Reference lists of retrieved articles were sought. Study selection Study designs of evaluations included in the review Randomised controlled trials (RCTs) on the efficacy of warfarin sodium in the primary prevention of stroke in chronic non-valvular atrial fibrillation were included. Specific interventions included in the review The specific intervention was anticoagulation, i.e. warfarin

1995 DARE.

1025. Antiarrhythmic prophylaxis vs warfarin anticoagulation to prevent thromboembolic events among patients with atrial fibrillation: a decision analysis

Antiarrhythmic prophylaxis vs warfarin anticoagulation to prevent thromboembolic events among patients with atrial fibrillation: a decision analysis Antiarrhythmic prophylaxis vs warfarin anticoagulation to prevent thromboembolic events among patients with atrial fibrillation: a decision analysis Antiarrhythmic prophylaxis vs warfarin anticoagulation to prevent thromboembolic events among patients with atrial fibrillation: a decision analysis Middlekauff H R, Stevenson W G, Gornbein J A Authors (...) ' objectives To establish the most efficacious strategy to prevent thromboembolism associated with atrial fibrillation. Searching MEDLINE was searched from 1966 to 1992, using the terms 'quinidine', 'warfarin', or 'amiodarone' with 'atrial fibrillation'. References of retrieved articles were checked. Only English language papers were included. Study selection Study designs of evaluations included in the review Randomised controlled trials (RCTs) with a minimum follow-up of 3 months. For amiodarone therapy

1995 DARE.

1026. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation

Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation Gage B, Cardinalli A, Albers G, Owens D Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Warfarin sodium, for the prevention of stroke in patients who have nonvalvular atrial fibrillation (NVAF), with or without additional stroke risk factors. Type of intervention Primary prevention and secondary prevention. Economic study type Cost-effectiveness analysis. Study population

1995 NHS Economic Evaluation Database.

1027. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. (PubMed)

Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Warfarin is an established treatment for prevention of ischaemic stroke in patients with atrial fibrillation, but the value of this agent relative to aspirin in unclear. In the first Stroke Prevention in Atrial Fibrillation (SPAF-I) study, direct comparison of warfarin with aspirin was limited by the small number of thromboembolic events. SPAF-II aims to address (...) the absolute rate of primary events by 1.2% per year (95% CI-1.7 to 4.1). The primary event rate per year was 3.6% with warfarin and 4.8% with aspirin (RR 0.73, p = 0.39). In this older group, the rate of all stroke with residual deficit (ischaemic or haemorrhagic) was 4.3% per year with aspirin and 4.6% per year with warfarin (RR 1.1). Warfarin may be more effective than aspirin for prevention of ischaemic stroke in patients with atrial fibrillation, but the absolute reduction in stroke rate by warfarin

1994 Lancet

1028. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. (PubMed)

Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Several studies have established the value of anticoagulation for primary prevention of thromboembolic events in patients with non-rheumatic atrial fibrillation (NRAF). However, in patients with a recent transient ischaemic attack (TIA) or minor ischaemic stroke the preventive benefit of anticoagulation or aspirin remains unclear

1993 Lancet

1029. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. (PubMed)

Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. Nonrheumatic atrial fibrillation is common among the elderly and is associated with an increased risk of stroke. We investigated whether anticoagulation with warfarin would reduce this risk.We conducted a randomized, double-blind, placebo-controlled study to evaluate low-intensity anticoagulation with warfarin (prothrombin (...) -time ratio, 1.2 to 1.5) in 571 men with chronic nonrheumatic atrial fibrillation; 525 patients had not previously had a cerebral infarction, whereas 46 patients had previously had such an event. The primary end point was cerebral infarction; secondary end points were cerebral hemorrhage and death.Among the patients with no history of stroke, cerebral infarction occurred in 19 of the 265 patients in the placebo group during an average follow-up of 1.7 years (4.3 percent per year) and in 4 of the 260

1992 NEJM

1030. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. (PubMed)

The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. Nonrheumatic atrial fibrillation increases the risk of stroke, presumably from atrial thromboemboli. There is uncertainty about the efficacy and risks of long-term warfarin therapy to prevent stroke.We conducted an unblinded, randomized, controlled trial of long-term, low-dose warfarin therapy (target prothrombin (...) -time ratio, 1.2 to 1.5) in patients with nonrheumatic atrial fibrillation. The control group was not given warfarin but could choose to take aspirin.A total of 420 patients entered the trial (212 in the warfarin group and 208 in the control group) and were followed for an average of 2.2 years. Prothrombin times in the warfarin group were in the target range 83 percent of the time. Only 10 percent of the patients assigned to receive warfarin discontinued the drug permanently. There were 2 strokes

1990 NEJM

1031. Preliminary report of the Stroke Prevention in Atrial Fibrillation Study. (PubMed)

Preliminary report of the Stroke Prevention in Atrial Fibrillation Study. Atrial fibrillation, even in the absence of rheumatic valvular disease, predisposes patients to embolic complications, but the role of antithrombotic therapy in the prevention of such complications has not been fully clarified. We therefore performed a randomized, placebo-controlled trial to evaluate warfarin and aspirin individually as prophylaxis against ischemic stroke and systemic embolism (the primary events (...) in patients with atrial fibrillation due to causes other than rheumatic valvular disease. The relative benefits of aspirin and warfarin remain unclear, and the trial is continuing in order to address this issue.

1990 NEJM

1032. Measuring blood pressure in the elderly: does atrial fibrillation increase observer variability? (PubMed)

Measuring blood pressure in the elderly: does atrial fibrillation increase observer variability? To compare the interobserver and intraobserver variability of blood pressure measurements in geriatric patients in atrial fibrillation and in sinus rhythm.Prospective assessment of blood pressure measurements carried out in random order in two groups of elderly patients by five doctors unaware of the aims of the study.Acute assessment wards for geriatric medicine, Cardiff Royal Infirmary.50 Elderly (...) patients in sinus rhythm and 50 in atrial fibrillation.Interobserver and intraobserver variability of blood pressure measurements in the two groups expressed as the coefficient of variability and compared by the Mann-Whitney U test.Interobserver variability was significantly greater in the patients with atrial fibrillation for both systolic and diastolic pressures. Intraobserver variability was significantly greater in the atrial fibrillation group for diastolic pressures but the difference

Full Text available with Trip Pro

1990 BMJ

1033. Atrial fibrillation and antithrombotic prophylaxis: a prospective meta-analysis. (PubMed)

Atrial fibrillation and antithrombotic prophylaxis: a prospective meta-analysis. 2563476 1989 03 16 2015 06 16 0140-6736 1 8633 1989 Feb 11 Lancet (London, England) Lancet Atrial fibrillation and antithrombotic prophylaxis: a prospective meta-analysis. 325-6 Walker M D MD eng Letter England Lancet 2985213R 0140-6736 AIM IM Atrial Fibrillation complications Humans Meta-Analysis as Topic Middle Aged Prospective Studies Thrombosis prevention & control 1989 2 11 1989 2 11 0 1 1989 2 11 0 0 ppublish

1989 Lancet

1034. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. (PubMed)

Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. From November, 1985, to June, 1988, 1007 outpatients with chronic non-rheumatic atrial fibrillation (AF) entered a randomised trial; 335 received anticoagulation with warfarin openly, and in a double-blind study 336 received aspirin 75 mg once daily and 336 placebo. Each patient was followed up for 2 years or until termination

1989 Lancet

1035. Is a controlled trial of long-term oral anticoagulants in patients with stroke and non-rheumatic atrial fibrillation worthwhile? (PubMed)

Is a controlled trial of long-term oral anticoagulants in patients with stroke and non-rheumatic atrial fibrillation worthwhile? A controlled randomised trial large enough to assess the value of anticoagulating stroke patients in atrial fibrillation would be difficult to conduct in the UK and the results would be applicable to only a small proportion of stroke patients. It would be more worthwhile to organise a trial that also assessed the value of other treatments that are simpler (...) and applicable to all stroke patients. A trial that assessed the value of aspirin and beta-blockers against control in all stroke patients would not cost much more than one restricted to comparing anticoagulants against control in patients with stroke and atrial fibrillation but would provide information of more relevance to the management of patients with stroke in the UK.

1986 Lancet